Sakar Healthcare Limited Stock Current Valuation
| SAKAR Stock | 303.15 12.10 4.16% |
Valuation analysis of Sakar Healthcare helps investors to measure Sakar Healthcare's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Sakar Healthcare's Change In Cash is very stable compared to the past year. As of the 2nd of December 2024, Other Cashflows From Financing Activities is likely to grow to about 742.5 M, while Cash is likely to drop about 2.2 M. Fundamental drivers impacting Sakar Healthcare's valuation include:
Price Book 2.5134 | Enterprise Value 7.4 B | Enterprise Value Ebitda 18.1405 | Price Sales 4.0633 | Trailing PE 58.0603 |
Fairly Valued
Today
Please note that Sakar Healthcare's price fluctuation is very steady at this time. Calculation of the real value of Sakar Healthcare is based on 3 months time horizon. Increasing Sakar Healthcare's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sakar Healthcare is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sakar Stock. However, Sakar Healthcare's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 303.15 | Real 307.61 | Hype 302.04 | Naive 306.8 |
The intrinsic value of Sakar Healthcare's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sakar Healthcare's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sakar Healthcare Limited helps investors to forecast how Sakar stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sakar Healthcare more accurately as focusing exclusively on Sakar Healthcare's fundamentals will not take into account other important factors: Sakar Healthcare Limited Company Current Valuation Analysis
Sakar Healthcare's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sakar Healthcare Current Valuation | 7.38 B |
Most of Sakar Healthcare's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sakar Healthcare Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sakar Healthcare Limited has a Current Valuation of 7.38 B. This is 48.6% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all India stocks is 55.59% higher than that of the company.
Sakar Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sakar Healthcare's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sakar Healthcare could also be used in its relative valuation, which is a method of valuing Sakar Healthcare by comparing valuation metrics of similar companies.Sakar Healthcare is currently under evaluation in current valuation category among its peers.
Sakar Fundamentals
| Return On Equity | 0.049 | ||||
| Return On Asset | 0.039 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 7.38 B | ||||
| Shares Outstanding | 21.75 M | ||||
| Price To Book | 2.51 X | ||||
| Price To Sales | 4.06 X | ||||
| Revenue | 1.54 B | ||||
| Gross Profit | 604.47 M | ||||
| EBITDA | 393.27 M | ||||
| Net Income | 116.71 M | ||||
| Cash And Equivalents | 933 K | ||||
| Total Debt | 793.52 M | ||||
| Book Value Per Share | 243.80 X | ||||
| Cash Flow From Operations | 244.67 M | ||||
| Earnings Per Share | 5.31 X | ||||
| Number Of Employees | 325 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 6.71 B | ||||
| Total Asset | 3.95 B | ||||
| Retained Earnings | 805.36 M | ||||
| Working Capital | 14.24 M | ||||
| Net Asset | 3.95 B |
About Sakar Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sakar Healthcare Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sakar Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sakar Healthcare Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Sakar Stock
Sakar Healthcare financial ratios help investors to determine whether Sakar Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sakar with respect to the benefits of owning Sakar Healthcare security.